Physical activity and physical fitness among children and adolescents after the onset of the COVID-19 pandemic in the WHO European Region: a systematic review protocol

Helena Ludwig-Walz 1,1, Waldemar Siemens 1,2,3, Sarah Heinisch,4 Indra Dannheim 5,6, Julika Loss,7 Martin Bujard 1,8

ABSTRACT

Introduction The implementation of COVID-19 pandemic-related restrictions resulted in limitations for physical activity (PA) opportunities, which may have initiated a longer-term behavioural change. The protocol describes the methodology for a planned systematic review that aims to summarise changes in PA and physical fitness (PF) in children and adolescents in the WHO European Region after the onset of the COVID-19 pandemic.

Methods and analysis The protocol adheres to the ‘Preferred Reporting Items for Systematic Review and Meta-Analysis for Protocols’ (PRISMA-P) statement. Using a peer-reviewed search strategy according to the evidence-based checklist ‘Peer Review of Electronic Search Strategies’ (PRESS), we will perform a systematic literature search in seven databases. Inclusion criteria are all primary studies that gathered data on children and adolescents ≤19 years living in the WHO European Region and made a comparison to pre-pandemic data. Primary outcomes are PA and PF. We will assess the risk of bias with the ‘Risk of Bias Instrument for Non-Randomized Studies of Exposures’ (ROBINS-E). The ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) approach will be used for the evaluation of the certainty of evidence. Also, subgroup analyses will be performed (eg, for gender, age, stringency of pandemic restrictions).

Ethics and dissemination Ethical approval is not required, as primary data will not be collected in this study. The results will be presented in a peer-reviewed publication and at congresses relevant to the research field.

PROSPERO registration number CRD42023395871.

INTRODUCTION

Physical activity (PA) and physical fitness (PF) in children and adolescents are accompanied by a variety of physical, mental and cognitive health benefits.1–3 This comprises, most importantly, improved cardiometabolic health, mental health, cognitive function, school achievement as well as reduced risk for metabolic syndrome and adiposity.3–8 PA and PF—positively influencing each other—in pre-adult years are strongly related to levels in adulthood.3,9,10 Hence, they have an immediate impact on health2,11 and disease burden12 later in life. In the updated global guidelines, the WHO has given a strong recommendation of at least an average of 60 min daily of moderate-to-vigorous PA for children and adolescents.1 Looking at PA before the COVID-19 pandemic, both globally and for European children and adolescents, it has been concluded that the vast majority of children (71%) and adolescents (75–86%) do not undertake sufficient PA in their daily lives; thereby females, older children and adolescents were...
With the onset of the COVID-19 pandemic, numerous public health and social measures (PHSM) were implemented to minimise the spread of the virus. The measures focused mainly on a reduction of social contacts, which led to major restrictions and adaptations in the daily life of the children and adolescents. This included closure of kindergartens, schools and public places, the halting of youth sports and school-based PA, restriction of contact with peers, modifications in family life due to home office and quarantine regulations, resulting in limited access and opportunities for PA. Some of these restrictions, such as school and kindergarten closures, persisted for many months, with broad variability among European countries. Global systematic reviews have documented a decline in total PA during the COVID-19 pandemic ranging from 11 to 91 min/day, respectively, a reduction of 20% for total PA or 28% for moderate-to-vigorous PA and also named relevant subgroups (e.g., older youth, lower social status, girls/females). There are indications that PHSM-related school closures could have intensified the decline, and other public health relevant behaviours were suboptimally influenced. Also, comparisons in primary studies of PF before and during the COVID-19 pandemic show a decline in youths’ PF skills.

However, there are still important research gaps concerning PA and PF of children and adolescents. At present, no systematic review addresses the changes during COVID-19 pandemic in the WHO European Region for PA and PF among children and adolescents. A preliminary investigation revealed several primary European studies with indifferent results for PA. Further, the study results varied in methodological approach, the change magnitude and the diagnostic instruments used. For PF, there is no summary of primary studies at all. Additionally, the measures chosen to control the COVID-19 pandemic varied (greatly) depending on the country. From previous meta-analyses, it is known that the stringency of measures had an essential influence on the health of children and adolescents. Therefore, the inclusion and consideration of the stringency of measures is an imperative determinant for indicating possible consequences on PA and PF. Also, the length of lockdown measures and the time period after lifting PHSM could be important determinants for youths’ PA and PF. Considering the WHO European Region, different stringencies and lengths can be compared in geographical proximity, which allows for a quasi-experimental design. Further, previous reviews have mainly investigated the immediate impact of the COVID-19 pandemic on PA due to limited data availability. However, it is of high public health relevance to know how the pandemic restrictions have affected the PA and PF behaviour of children and adolescents in a medium-term perspective. There is limited evidence to date concerning the various subgroups in the population of children and adolescents (e.g., gender, age, social status, time of measurement) who are particularly affected by pandemic-related restrictions. Addressing these research gaps has major public health relevance in providing a basis for investigators, providers and policy makers to guide decision-making, as well as to improve the health and well-being of children and adolescents.

Therefore, we intend to conduct a systematic review that aims to critically synthesise the evidence regarding the impact of the COVID-19 pandemic on PA and PF among children and adolescents in countries of the WHO European Region compared with a pre-pandemic baseline, differentiating the following research objectives:

1. Estimation of the change of PA and PF among children and adolescent in countries of the WHO European Region (with published data) after the onset of the COVID-19 pandemic compared with a pre-pandemic baseline.
2. Evaluation of the impact of the PHSM stringency and length during the COVID-19 on PA and PF among children and adolescents in countries of the WHO European Region (with published data).
3. Determination of the effect changes of PA and PF over time, allowing for the analysis of possible recovery effects after the end of most restrictions during 2021, under consideration of studies until January 2023 (date of publication).
4. Analyses of changes in PA and PF for central demographic and socioeconomic subgroups.

METHODS AND ANALYSIS

This systematic review protocol followed the Preferred Reporting Items for Systematic Review and Meta-Analysis for Protocols (PRISMA-P) statement (online supplementary table S1) and was registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD42023395871). The final systematic review will be conducted according to the PRISMA statement and will follow the guidelines of the actual Cochrane Handbook for Systematic Reviews.

Eligibility criteria

We formulated the eligibility criteria in accordance with the Population Exposure Comparison and Outcome (PECO) scheme, presented in table 1.

Information sources

We will search in seven electronic databases (PubMed, Embase, Sports Medicine & Education Index, PsycINFO, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL) and WHO COVID-19 Research
Database (including pre-prints) for articles published between 1 November 2019 and 31 January 2023. Further, we will perform forward citation tracking and check cited references of all included studies and related systematic reviews and meta-analyses. We will also check study registers (eg, PROSPERO, clinicaltrials.gov; see online supplemental table S2), conference submissions and websites of key organisations (online supplemental table S3). We will contact study authors to receive information of study status or data, if applicable.

**Search strategy**

The search strategy combined terms related to (1) children and adolescents, (2) PA and PF and (3) the COVID-19 pandemic, using the Boolean operator.

**Study records**

The results of the literature search will be uploaded to the recommended EPPiReviewer Web software and screened automatically for duplicates. All screening steps will be conducted in EPPiReviewer, afterwards an export of the final studies to Citavi, V.6.4.0.33, will be performed.

**Selection process**

In accordance with the inclusion and exclusion criteria (table 1), we will conduct study selection in a two-stage process. First, all publications will be screened at title.
Data collection process

A data extraction form will be developed predicated on previous reviews and pilot tested. Two reviewers (HL-W, SH) will extract the data independently and compare it afterwards, any discrepancies will be resolved by discussion or with the involvement of a further reviewer (MB). If the provided data in the published studies are insufficient, authors will be asked to provide further information.

Data items

It is planned to extract and summarise the study data in three tables: (1) characteristics of included studies, (2) summary of effect estimates and (3) summary of findings. In the table ‘Characteristics to be extracted from included studies’, information from five categories will be extracted for a descriptive study overview. The categories are outlined in table 2.

We will place a particular focus on the impact of PHSM stringency during the COVID-19 pandemic on PA and PF changes among children and adolescents (research objective 2) by using the validated Oxford COVID-19 Stringency Index. The index is computed using nine metrics of social distancing policy: school closures, workplace closures, cancellation of public events, restrictions on public gatherings, closures of public transport, stay-at-home requirements, public information campaigns, restrictions on internal movements and international travel controls; it has a total score estimate that ranges from 0 (no restrictions) to 100 (most stringent restrictions). A mean score will be calculated for each study measurement period during the COVID-19 pandemic. In accordance with the COVIDSurg Collaborative, we will specify three cut-off points: light restrictions (index < 20), moderate lockdowns (index 20–60) and full lockdowns (index > 60). Further, we will specifically consider the School Closure Index, also implemented in the Oxford COVID-19 Stringency Index, which records closings of schools and universities. The index range is from 0 to 3: 0 for no measures, 1 for recommended closings or changes in school operations, 2 for partially school closures and 3 for closing of all school levels. Therefore, we will define the following cut-offs: no or few alterations compared with a pre-COVID-19 situation (index < 2) and partial or full school closure (index ≥ 2). In addition, we will also look at the total length of the restriction measures and, if possible, the time period from removing restrictions.

The ‘Summary of effect estimates’ table will include the effect estimates for before and during COVID-19 and abstract level. For publications that appear to meet the inclusion criteria or where there is uncertainty, the study’s full text will be obtained. Second, the full texts will be screened for a final selection of the studies to be included. Publications will be screened independently in teams of two reviewers (HL-W, ID, SH), any discrepancies will be discussed and, if necessary, resolved by a third author (MB). In the case of duplicate publications or multiple reports of a study, we will maximise information yield by collecting all available data and using the complete data set. Publications with the same study population with several pandemic measurement points will be considered individually. We will report reasons for full-text study exclusion in the online supplemental information. The screening process will be illustrated using the PRISMA flow diagram.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Characteristics to be extracted from included studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
<td>Planned data for extraction</td>
</tr>
</tbody>
</table>
| Study information | ▶ First author  
▶ Year of publication  
▶ Country  
▶ Study type |
| Population and setting | ▶ Sample size (% female) at pre-pandemic baseline and during COVID-19 pandemic  
▶ Age (mean or median; SD or range) |
| COVID-19 determinants | ▶ Time point (month/year) of data measurement  
▶ Policy restrictions in the measurement period, described by using the Oxford COVID-19 Stringency Index and the School Closure Index as a proxy indicator  
▶ Length of restriction measures, if applicable  
▶ Time period of removed restrictions, if applicable  
▶ Duration of follow-up |
| Pre-pandemic baseline | ▶ Time point (month/year) of data measurement  
▶ Link between pre-pandemic and during pandemic population (same population, similar population, cross-sectional population sample) |
| Outcome | Physical activity (PA)  
▶ Self-reported/parent-reported diagnostic instrument  
▶ Name of used instrument  
▶ Estimated time frame (weekday/weekend)  
▶ Predefined cut-off points, if applicable  
▶ Symptom reporter (self-reported or parent-report)  
▶ Validation information  
▶ Device-based measurement (based on Tanaka et al)  
▶ Brand of used instrument  
▶ Number of days worn  
▶ Weekend capture (yes/no)  
▶ Predefined cut-off points, if applicable  
▶ Validation information  
▶ Physical fitness (PF)  
▶ Physical fitness assessment instrument  
▶ Name of used instrument  
▶ Setting (e.g., school, sports club)  
▶ Symptom reporter (e.g., teacher, research staff)  
▶ Validation information |

pandemic, change of PA or PF, adjustment variables (if reported), considered subgroups and the risk of bias for each study. In a ‘Summary of findings’ table according to GRADE, we will present the main findings of the review and the certainty of evidence per effect estimate of each outcome.53

Outcomes
The primary outcomes will comprise PA and PF. In accordance with the WHO, we will define PA as any bodily movement that requires energy expenditure during leisure time (either structured or unstructured by an organisation), at school/other settings or for getting from one place to another.1 Changes in the duration of daily PA will be (1) transferred (or calculated) in minutes per day and SD or (2) differences between scores with SD will be calculated. If possible, we will further separate the outcome in total PA and moderate-to-vigorous intensity PA (according to the definition of the WHO1 and the Centers for Disease Control and Prevention).56 The outcome PF is defined as attributes that children and adolescents achieve that relates to the ability to perform PA (eg, cardiorespiratory endurance, muscular endurance/strength, flexibility).57

In a preliminary analysis of the literature, we found that both PA and PF were measured with a variety of instruments. In order to ensure a high-quality analysis, we decided to include only validated instruments in this review. No restrictions will be defined on measurements number during the COVID-19 pandemic. If various pre-pandemic measurement dates will be available, we will consider the most appropriate or the latest time point for effect estimate calculation. We will extract adjusted values; if these are not available, we will select unadjusted results. Effect estimate will be reported with a 95% CI.

Risk of bias
From reviews that have already been published26 36 and our preliminary analysis, we expect primarily observational studies. Hence, two review authors (HL-W, SH) will independently assess the risk of bias using the instrument for non-randomised studies of exposures (ROBINS-E),38 a modification of the risk of bias in non-randomised studies of interventions (ROBINS-I) tool.59 This instrument includes seven items: (1) risk of bias due to confounding, (2) risk of bias arising from measurement of the exposure, (3) risk of bias in selection of participants into the study, (4) risk of bias due to post-exposure interventions, (5) risk of bias due to missing data, (6) risk of bias arising from measurement of the outcome and (7) risk of bias in selection of the reported result. The possible ratings for each risk of bias item include: ‘low’, ‘some concerns’, ‘high risk of bias’ or ‘very high risk of bias’. Lastly, a complete risk of bias rating will be done for each study. We will not exclude studies with high or very high risk of bias from the further analyses. However, we will differentiate between studies that are rated as low/some concerns (=low) risk of bias and high/very high (=high) risk of bias in order to address potential confounding.

The risk of bias ratings will be visualised as ‘traffic light’ plots of the domain-level judgements for each individual result and ‘weighted bar plots’ of the distribution of risk-of-bias judgements within each bias domain, using the tool robvis.40

Data synthesis
First, we will provide a ‘Summary effect estimates’ table for each study with absolute changes for PA and PF before and during the COVID-19 pandemic, grouped by country and risk of bias (see the Data items section). Second, if at least three of the included studies with different study populations are sufficiently homogeneous in terms of study design, participant characteristics (age, gender) and effect estimates, we will conduct meta-analyses. For this, equal effect estimates should be available or it should be possible to convert them into a common effect estimate. We will calculate standardised mean differences (SMD) to provide a pooled effect if the same outcome was measured with different instruments and to permit inter-study comparisons. SMD effect sizes will be considered as small, medium and large for 0.2, 0.5 and 0.8, respectively.61 To estimate the pooled change in PA and PF, mean changes and SD of the change will be combined in random-effects meta-analyses using the inverse-variance method. If SD are missing, we will calculate them from p values, CIs or SEs, if available or contact the study authors.40 To explore variations due to age, gender, social status, seasonality, measurement instrument and risk of bias in individual studies as possible effect modifiers,17 we will conduct subgroup analyses. Also, the stringency of pandemic-related measures will be considered by conducting comparative analyses between full versus moderate lockdowns (Oxford Stringency Index >60 vs ≤60) and school closures versus no school closures (School Closure Index ≥2 vs<2) considering also the total length of PHSM and, if possible, the time period of removed restrictions. Results from adjusted analysis will get preference in the meta-analysis to provide a more conservative estimate (a sensitivity analysis will be performed when including unadjusted effect estimates). When both parent and self-rated data are provided, the self-rated data will be chosen for meta-analysis.62 Results of the meta-analysis will be illustrated using forest plots.

We will assess heterogeneity across studies by visual interpretation of the forest plots, applying I² statistic,63 and the calculation of prediction intervals when ≥3 studies are included in meta-analyses.54–66 Heterogeneity will be interpreted as substantial if I² is greater than 50%.65 If substantial heterogeneity is detected, we will make efforts to explain it by performing subgroup analyses, sensitivity analyses and/or meta-regressions.64 For performing meta-regression analyses, a minimum of 10 studies will be assumed per examined variable.64

The analyses will be conducted with R Studio V.4.2.167 using the package meta.68 If a statistical pooling (meta-analysis) appears to be inappropriate, for example, if
study designs differ considerably, a tabular, graphical or narrative synthesis will be provided.

**Sensitivity analysis**

We will conduct sensitivity analyses to determine whether the pooled results are robust. Therefore, the meta-analysis will be repeated with different comparison categories, for example, low versus high risk of bias, cohort versus cross-sectional studies (or randomized controlled trial, if available) and adjusted versus unadjusted effect estimates.

**Publication bias**

We will also consider potential publication bias by visual interpretation of (contour-enhanced) funnel plots. Further, we will apply the Egger’s test, when a minimum of 10 studies are included in a meta-analysis.

**Certainty of evidence**

We will evaluate the certainty of evidence for PA (min/day, scores) and PF using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach adapted to the use of non-randomised studies. GRADE considers five domains for downgrading (risk of bias, inconsistency, indirectness, imprecision and publication bias) and also three domains for upgrading (large effects, dose response and opposing plausible residual bias and confounding). The use of the risk of bias instrument for non-randomised studies will allow us to start at ‘high’ initial certainty of evidence within GRADE. A detailed description of the downgrading and upgrading determinants will be provided in the publication of the final systematic review. Two reviewers (HL-W, WS) will independently evaluate the certainty of evidence and then compare the ratings; discrepancies will be resolved by discussion or by involving a third reviewer (MB). GRADE finally defines for each outcome four certainty-of-evidence levels: high, moderate, low or very low. We will summarise the certainty of evidence in a ‘Summary of findings’ table, extended by evidence profiles with more detailed explanations in the online supplemental information.

**DISCUSSION**

There is an urgent public health need to identify possible medium-term and longer-term changes in PA and PF of children and adolescents in the WHO European Region. These changes need to be analysed by gender, age group, time of measurement and socioeconomic characteristics. To our knowledge, this will be the first systematic review searching for and summarising the evidence regarding changes of PA and PF among children and adolescents in the WHO European Region after the onset of the COVID-19 pandemic in comparison to pre-pandemic baselines and using validated measurement instruments.

Some limitations and challenges of the intended review also need to be considered. A limitation may be the heterogeneity in reporting and measuring of outcomes. Especially the identification of validated measurements for PF is a foreseeable challenge of the review as the tools used in the literature are very heterogeneous. Although we chose clinically relevant subgroups, we are aware that subgroup analyses will be explorative and may result in false-positive findings due to multiple testing. The review will present only medium-term effects of pandemic-related restrictions, not long-term effects because of lack of data. Since we do not expect to consider studies meeting our strict criteria for all 53 countries of the WHO European Region, our findings will not be generalisable to all of Europe. But we aim to use the country-specific variation of PHSM measures and school closures in order to consider their association with PA and PF.

We intend to include heterogeneous study designs (eg, cohort, panel, cross-sectional, retrospective survey), therefore, different characteristics of these designs have to be considered. Cohort or panel studies examine the same individuals but cover a longer period between survey dates, so that children and adolescents are older and changes in PA and PF behaviour could result from this. This allows for comparison within as well as comparison between different individuals. Cross-sectional studies analyse individuals of the same age or in similar settings, but not the identical samples of respondents, which can bias the results. Retrospective surveys are subject to recall bias. We will address these limitations by applying the recommended ROBINS-E tool, considering especially four (from seven) domains: ‘risk of bias due to confounding’ (domain 1), ‘risk of bias arising from measurement of the exposure’ (domain 2), ‘risk of bias in selection of participants into the study’ (domain 3) and ‘risk of bias due to missing data’ (domain 5).

The restrictive inclusion criteria regarding a pre-pandemic baseline and the utilisation of validated instruments may lead to a consideration of mainly quantitative panel studies. However, such a focus seems to be adequate for our research questions and for allowing meta-analysis. Although analyses of country-specific and time-specific contexts of PHSM are intended by using the Oxford Stringency Index and other subgroup comparisons (eg, age, gender, time of measurement, length of restriction, risk of bias, and measurement instruments), not entirely all factors influencing the change in PA and PF can be completely covered. The central strength of the review is the use of different state-of-the-art approaches such as PRISMA, PRESS, ROBINS-E and GRADE. Additionally, we adhere to methodological recommendations of the Cochrane Handbook and the restrict data extraction to validated measurements. By highlighting country-specific differences and the impact of pandemic-related restrictions such as school closures on PA and PF, conclusions might also be drawn regarding the management of future crises or pandemics. The findings will close relevant evidence gaps and will provide implications for practitioners, policy makers, families and stakeholders.

Ethics and dissemination

Ethical approval is not required as no primary data will be collected for the systematic review. The results will be published in a peer-reviewed journal and presented at congresses relevant to the research field.

Author affiliations

1 Federal Institute for Population Studies, Wiesbaden, Germany
2 Faculty of Medicine, Institute for Evidence in Medicine, Medical Center - University of Freiburg, Freiburg, Germany
3 Cochrane Germany Foundation, Freiburg, Germany
4 University of Education, Karlsruhe, Germany
5 Regional Innovative Centre of Health and Quality of Life Fulda (RIGL), Fulda, Germany
6 Department of Nutritional, Food and Consumer Sciences, Fulda University of Applied Sciences, Fulda, Germany
7 Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany
8 Institute of Medical Psychology, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany

Acknowledgements

We would like to thank Sabrina Schlesinger for peer-reviewing our PubMed search strategy according to the PRESS guidelines.

Contributors

HL-W and MB formulated the research question with clinical and methodological feedback from WS. All authors contributed to the study conception and design. Literature screening, data extraction and risk-of-bias assessment will be performed by HL-W, SH and ID. Meta-analysis and GRADE assessment will be conducted by HL-W and WS. The first draft of the protocol manuscript was written by HL-W and revised by MB; all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were not involved in the design, conduct, or reporting or dissemination plans of this research.

Patient consent for publication

Not applicable.

Provenance and peer review

Not commissioned; externally peer reviewed.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been vetted by external peer reviewers. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Helena Ludwig-Walz http://orcid.org/0000-0003-1558-8241
Waldemar Siemens http://orcid.org/0000-0003-4238-5327
Indra Danneheim http://orcid.org/0000-0002-4478-7808
Martin Bujard http://orcid.org/0000-0002-3603-4160

REFERENCES

25 Pang JCY, Chan ELN, Lau HMC, et al. The impacts of physical activity on psychological and behavioral problems, and changes in physical activity, sleep and quality of life during the COVID-19


65 Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549(d549).


SUPPLEMENT

Physical activity and physical fitness among children and adolescents after the onset of the COVID-19 pandemic in the WHO European Region: A systematic review protocol

Helena LUDWIG-WALZ; Waldemar SIEMENS; Sarah HEINISCH; Indra DANNHEIM; Julika LOSS;
Martin BUIJARD

Table S1: Preferred Reporting Items for Systematic review and Meta-Analysis Protocols ...................... 2
Table S2: Search in registers .................................................................................................................... 4
Table S3: Search on websites of key organizations .................................................................................. 4
Table S4: Search strategies for all databases ........................................................................................... 5
Table S1: Preferred Reporting Items for Systematic review and Meta-Analysis Protocols

<table>
<thead>
<tr>
<th>Section and topic</th>
<th>Item No</th>
<th>Checklist item</th>
<th>Location where item is reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADMINISTRATIVE INFORMATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identification</td>
<td>1a</td>
<td>Identify the report as a protocol of a systematic review</td>
<td>1</td>
</tr>
<tr>
<td>Update</td>
<td>1b</td>
<td>If the protocol is for an update of a previous systematic review, identify as such</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Registration</td>
<td>2</td>
<td>If registered, provide the name of the registry (such as PROSPERO) and registration number</td>
<td>3 and 7</td>
</tr>
<tr>
<td>Authors:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact</td>
<td>3a</td>
<td>Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author</td>
<td>1</td>
</tr>
<tr>
<td>Contributions</td>
<td>3b</td>
<td>Describe contributions of protocol authors and identify the guarantor of the review</td>
<td>26</td>
</tr>
<tr>
<td>Registration</td>
<td>2</td>
<td>If registered, provide the name of the registry (such as PROSPERO) and registration number</td>
<td>3 and 7</td>
</tr>
<tr>
<td>Authors:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact</td>
<td>3a</td>
<td>Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author</td>
<td>1</td>
</tr>
<tr>
<td>Contributions</td>
<td>3b</td>
<td>Describe contributions of protocol authors and identify the guarantor of the review</td>
<td>26</td>
</tr>
<tr>
<td>Amendments</td>
<td>4</td>
<td>If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Support:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sources</td>
<td>5a</td>
<td>Indicate sources of financial or other support for the review</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Sponsor</td>
<td>5b</td>
<td>Provide name for the review funder and/or sponsor</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Role of sponsor or funder</td>
<td>5c</td>
<td>Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol</td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>6</td>
<td>Describe the rationale for the review in the context of what is already known</td>
<td>7</td>
</tr>
<tr>
<td>Objectives</td>
<td>7</td>
<td>Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)</td>
<td>9, Table 1</td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>8</td>
<td>Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review</td>
<td>9, Table 1</td>
</tr>
<tr>
<td>Information sources</td>
<td>9</td>
<td>Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage</td>
<td>10</td>
</tr>
<tr>
<td>Search strategy</td>
<td>Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study records:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data management</td>
<td>11a Describe the mechanism(s) that will be used to manage records and data throughout the review.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection process</td>
<td>11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data collection process</td>
<td>11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data items</td>
<td>12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcomes and prioritization</td>
<td>13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data synthesis</td>
<td>15a Describe criteria under which study data will be quantitatively synthesised.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I², Kendall’s τ).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15d If quantitative synthesis is not appropriate, describe the type of summary planned.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meta-bias(es)</td>
<td>16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confidence in cumulative evidence</td>
<td>17 Describe how the strength of the body of evidence will be assessed (such as GRADE).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S2: Search in registers

<table>
<thead>
<tr>
<th>Register</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Prospective Register of Systematic Reviews</td>
<td><a href="https://www.crd.york.ac.uk/prospero/">https://www.crd.york.ac.uk/prospero/</a></td>
</tr>
<tr>
<td>Clinical Trials.gov</td>
<td><a href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</a></td>
</tr>
</tbody>
</table>

Table S3: Search on websites of key organizations

<table>
<thead>
<tr>
<th>Key organization</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centers for Disease Control and Prevention (CDC)</td>
<td><a href="https://www.crd.york.ac.uk/prospero/">https://www.crd.york.ac.uk/prospero/</a></td>
</tr>
<tr>
<td>Council of Europe</td>
<td><a href="https://www.coe.int/de/web/portal">https://www.coe.int/de/web/portal</a></td>
</tr>
<tr>
<td>European Centre for Disease Prevention and Control</td>
<td><a href="https://www.ecdc.europa.eu/en">https://www.ecdc.europa.eu/en</a></td>
</tr>
<tr>
<td>European Union</td>
<td><a href="https://european-union.europa.eu/index_de">https://european-union.europa.eu/index_de</a></td>
</tr>
<tr>
<td>National Health Service</td>
<td><a href="https://www.nhs.uk/">https://www.nhs.uk/</a></td>
</tr>
<tr>
<td>Save the Children</td>
<td><a href="https://www.savethechildren.net/">https://www.savethechildren.net/</a></td>
</tr>
<tr>
<td>Sport England</td>
<td><a href="https://www.sportengland.org/">https://www.sportengland.org/</a></td>
</tr>
<tr>
<td>World Health Organization (WHO), Regional Office for Europe</td>
<td><a href="https://www.who.int/europe/about-us/about-who-europe/organization">https://www.who.int/europe/about-us/about-who-europe/organization</a></td>
</tr>
</tbody>
</table>
Table S4: Search strategies for all databases

<table>
<thead>
<tr>
<th>Database</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparison</th>
<th>Outcome</th>
<th>Species</th>
<th>Language</th>
</tr>
</thead>
</table>
Population:
Infant* OR toddler* OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child* OR schoolchild* OR ('school child' OR 'school child*'):ab,ti OR adolescen* OR juvenile* OR youth* OR teen* OR under*age* OR pubescen* OR 'pediatric'/exp OR pediatric* OR paediatric* OR ('pediatric*' OR 'school' OR 'school*'):ab,ti OR (kindergarten* OR kindergarten*):ab,ti

Intervention:
(covid*:ab,ti OR 'sars 2':ab,ti OR 'sars-cov-19':ab,ti OR 'sars-cov19':ab,ti OR 'sars-cov-19':ab,ti OR 'sars cov 19':ab,ti OR 'sarscov 19':ab,ti OR 'sars cov19':ab,ti OR 'sars-cov-2':ab,ti OR 'sars-cov2':ab,ti OR 'sars cov2':ab,ti OR 'sarscov2':ab,ti OR 'sars cov2':ab,ti OR 'sarscov2':ab,ti OR 'sars cov2':ab,ti OR 'severe acute respiratory syndrome':ab,ti OR 'severe acute respiratory disease':ab,ti OR 'coronavirus*':ab,ti OR 'corona virus*':ab,ti OR 'corona-virus*':ab,ti OR 'ncov*':ab,ti OR 'n cov*':ab,ti OR 'n cov':ab,ti OR 'novelcov*':ab,ti OR 'novel cov*':ab,ti OR 'novel-cov*':ab,ti OR 'severe acute respiratory syndrome coronavirus 2'/exp OR 'coronavirinae'/exp OR 'coronavirus'/exp) AND [01-11-2019]/sd NOT [31-12-3000]/sd

Pre-pandemic baseline included in the study (will be screened manually)

Outcome:
'exercise'/exp OR 'physical activity'/exp OR 'sport'/exp OR 'dancing'/exp OR 'motor activity'/exp OR (physical:ab,ti AND (activ*:ab,ti OR lifestyle:ab,ti OR 'life style':ab,ti)) OR exercise*:ab,ti OR fitness:ab,ti OR sport*:ab,ti OR 'physical exertion*' OR 'motor activ*':ab,ti OR 'train*':ab,ti OR 'physical effort*':ab,ti OR 'physical endurance':ab,ti OR 'physical condition*':ab,ti OR gymnastic*:ab,ti OR run:ab,ti OR runn*:ab,ti OR swim*:ab,ti OR walk*:ab,ti OR jogg*:ab,ti OR athletic*:ab,ti OR cycl*:ab,ti OR aerobic*:ab,ti OR move:ab,ti OR bicycl*:ab,ti

Species:
Humans (screened manually)

Language:
No limit
APA PsycInfo (via EBSCOhost)

**Population**

(TI (Infant* OR toddler* OR minors OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child OR child* OR children* OR schoolchild* OR schoolchild OR 'school child' OR 'school child*' OR adolescence* OR juvenile* OR youth* OR teen* OR under-age* OR pubescence* OR pediatrics OR pediatric* OR paediatric* OR 'school' OR under-age* OR pubescence* OR 'school*' OR kindergarten* OR 'kindergarten*'))) OR (AB (Infant* OR toddler* OR minors OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child OR child* OR children* OR schoolchild* OR schoolchild OR 'school child' OR 'school child*' OR adolescence* OR juvenile* OR youth* OR teen* OR under-age* OR pubescence* OR pediatrics OR pediatric* OR paediatric* OR 'school' OR under-age* OR pubescence* OR 'school*' OR kindergarten* OR 'kindergarten*'))

**Intervention**

(DE "COVID-19" OR DE "Coronavirus") OR (TI covid* OR AB covid*) OR (TI covid* OR AB covid*) OR (TI "SARS-CoV-2" OR AB "SARS-CoV-2") OR (TI "sars-2*" OR AB "sars-2") OR (TI "sars2*" OR AB "sars2") OR (TI "sars 2" OR AB "sars 2") OR (TI "sars-cov-19" OR AB "sars-cov-19") OR (TI "sars-cov19" OR AB "sars-cov19") OR (TI "sars cov-19" OR AB "sars cov-19") OR (TI "sarscov19" OR AB "sarscov19") OR (TI "sars cov 19" OR AB "sars cov 19") OR (TI "sarscov2" OR AB "sarscov2") OR (TI "sars-cov2" OR AB "sars-cov2") OR (TI "sarscov2" OR AB "sars-cov2") OR (TI "sars cov 2" OR AB "sars cov 2") OR (TI "sars2v" OR AB "sars2v") OR (TI "sars2" OR AB "sars2") OR (TI "sars 2" OR AB "sars 2") OR (TI "sars-cov" OR AB "sars-cov") OR (TI "sars-cov" OR AB "sars-cov") OR (TI "sars cov" OR AB "sars cov") OR (TI "sarscov" OR AB "sarscov") OR (TI "sars cov" OR AB "sars cov")

Pre-pandemic baseline included in the study (will be screened manually)

**Outcome**

Humans (screened manually)

**Limits**

No limit
Cochrane Library

Population
#1 MeSH descriptor: [Infant] explode all trees
#2 MeSH descriptor: [Child] explode all trees
#3 MeSH descriptor: [Adolescent] explode all trees
#4 MeSH descriptor: [Pediatrics] explode all trees
#5 MeSH descriptor: [Schools] explode all trees
#6 (Infant* OR toddler* OR minors OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child* OR schoolchild* OR schoolchild OR "school NEXT child*" OR adolescent* OR juvenil* OR youth* OR teen* OR under-age* OR pubescen* OR paediatric* OR paediatric* OR school* OR kindergarten* OR kindergarten*):ti,kw,ab
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6

Intervention
#8 MeSH descriptor: [COVID-19] explode all trees
#9 MeSH descriptor: [Coronavirus] explode all trees
#10 MeSH descriptor: [undefined] explode all trees
#11 (covid* OR sars-2 OR sars2 OR "sars NEXT 2" OR sars-cov-19 OR sars-cov19 OR sarscov-19 OR "sars NEXT cov NEXT 19" OR "sarscov NEXT 19" OR "sars NEXT cov19" OR sarscov19 OR SARS-CoV-2 OR sarscov2 OR sarscov2 OR "sars NEXT cov2" OR "sarscov NEXT 2" OR "sarscov NEXT cov2" OR "Severe NEXT Acute NEXT Respiratory NEXT Syndrome" OR "Severe NEXT Acute NEXT Respiratory NEXT disease" OR Coronavirus* OR corona-virus* OR "corona NEXT virus*" OR ncov* OR n-cov* OR "n NEXT cov*" OR novelcov* OR novel-cov* OR "novel NEXT cov*" OR "novel NEXT cov*"):ti,ab,kw (Word variations have been searched)
#12 #8 OR #9 OR #10 OR #11

Comparison
Pre-pandemic baseline included in the study *(will be screened manually)*
Outcome

#13  MeSH descriptor: [Exercise] explode all trees
#14  MeSH descriptor: [Sports] explode all trees
#15  MeSH descriptor: [Dancing] explode all trees
#16  MeSH descriptor: [Motor Activity] explode all trees
#17  MeSH descriptor: [Physical Exertion] explode all trees
#18  MeSH descriptor: [Exercise Movement Techniques] explode all trees
#19  MeSH descriptor: [Human Activities] explode all trees
#20  (((physical) AND (activ* OR lifestyle OR life-style OR "life style")) OR exercise* OR fitness OR sport* OR "physical exertion*" OR "motor activ*" OR "train*" OR "physical effort*" OR "physical endurance" OR "physical condition*" OR gymnastic* OR run OR runn* OR swim* OR walk* OR jogg* OR athletic* OR cycl* OR aerobic* OR move OR bicycl*):ti,ab,kw (Word variations have been searched)
#21  #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20
#22  #7 AND #12 AND #21
Humans (screened manually)

Limits

No limit
<table>
<thead>
<tr>
<th>Web of Science Core Collection</th>
<th>Population</th>
<th>Infan* OR toddler* OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child* OR children* OR schoolchild* OR schoolchild OR &quot;school child&quot; OR &quot;school child&quot; OR adolescen* OR juvenil* OR youth* OR teen* OR under<em>age</em> OR pubescen* OR kindergarten* OR kindergarten* (Topic)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intervention</td>
<td>covid* OR &quot;sars 2&quot; OR sarra OR sars-2 OR &quot;sars cov 19&quot; OR &quot;sars cov19&quot; OR &quot;sarscov 19&quot; OR sarscov OR &quot;sars-cov-19&quot; OR &quot;sars-cov19&quot; OR &quot;sars-cov-19&quot; OR &quot;sars-cov-2&quot; OR &quot;sarscov 2&quot; OR &quot;sars cov2&quot; OR sarscov OR &quot;sars cov 2&quot; OR &quot;sars-cov-2&quot; OR &quot;sars-cov2&quot; OR &quot;severe acute respiratory syndrome&quot; OR &quot;severe acute respiratory disease&quot; OR coronavirus* OR &quot;corona virus&quot;* OR &quot;corona-virus&quot;* OR ncor* OR &quot;n-cov&quot;* OR &quot;n cov&quot; OR novelcov* OR &quot;novel cov&quot;* OR &quot;novel cov*&quot; OR &quot;novel-cov*&quot; (Topic)</td>
</tr>
<tr>
<td></td>
<td>Comparison</td>
<td>Pre-pandemic baseline included in the study (will be screened manually)</td>
</tr>
<tr>
<td></td>
<td>Outcome</td>
<td>((physical) AND (activ* OR lifestyle OR life-style OR &quot;life style&quot;)) OR exercise* OR fitness OR sport* OR &quot;physical exertion&quot;* OR &quot;motor activ&quot;* OR &quot;train&quot;* OR &quot;physical effort&quot;* OR &quot;physical endurance&quot; OR &quot;physical condition&quot;* OR gymnastic* OR run OR runn* OR swim* OR walk* OR jogg* OR athletic* OR cycl* OR aerobic* OR move OR bicycl* (Topic)</td>
</tr>
<tr>
<td></td>
<td>Species</td>
<td>Humans (screened manually)</td>
</tr>
<tr>
<td></td>
<td>Language</td>
<td>No limit</td>
</tr>
</tbody>
</table>
### WHO COVID-19 database

**Population**
- (infant* toddler* OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child* OR children* OR schoolchild* OR schoolchild OR "school child" OR "school child" OR adolescent* OR juvenile* OR youth* OR teen* OR under*age* OR pubescen* OR kindergarten* OR kindergarten*)

**Intervention**
- (covid* OR "sars 2" OR sars2 OR sars-2 OR "sars cov 19" OR "sars cov19" OR "sarscov 19" OR sarscov19 OR "sars-cov-19" OR "sars-cov19" OR "sarscov-19" OR "sars-cov-2" OR "sarscov 2" OR "sars cov2" OR sarscov2 OR "sars cov 2" OR "sarscov-2" OR "sars-cov-2" OR "severe acute respiratory syndrome" OR "severe acute respiratory disease" OR coronavirus* OR "corona virus"* OR "corona-virus"* OR ncov* OR "n-cov"* OR "n cov" OR novelcov* OR "novel cov"* OR "novel-cov"*)

**Comparison**
- Pre-pandemic baseline included in the study *(will be screened manually)*

**Outcome**
- ((physical) AND (activ* OR lifestyle OR life-style OR "life style") OR exercise* OR fitness OR sport* OR "physical exertion"* OR "motor activ"* OR "train"* OR "physical effort"* OR "physical endurance" OR "physical condition"* OR gymnastic* OR run OR runn* OR swim* OR walk* OR jogg* OR athletic* OR cycl* OR aerobic* OR move OR bicycl*)

**Species**
- Humans *(screened manually)*

**Language**
- No limit
SPORTDiscus

Population
(Infant* toddler* OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child* OR children* OR schoolchild* OR schoolchild OR "school child" OR "school child" OR adolescen* OR juvenile* OR youth* OR teen* OR under*age* OR pubescen* OR kindergarten* OR kindergarten*)

Intervention
(covid* OR "sars 2" OR sars2 OR sars-2 OR "sars cov 19" OR "sars cov19" OR "sarscov 19" OR sarscov19 OR "sars-cov-19" OR "sars-cov19" OR "sarscov-19" OR "sars-cov2" OR "sars cov2" OR "sars cov2" OR "sars cov2" OR "sarscov 2" OR "sarscov 2" OR "sarscov 2" OR "sarscov2" OR "sars cov 2" OR "sarscov-2" OR "sars-cov2" OR "sars cov2" OR "sars cov2" OR "sars cov2" OR "sarscov-2" OR "sars-cov2")

Comparison
Pre-pandemic baseline included in the study (will be screened manually)

Outcome
((physical) AND (activ* OR lifestyle OR life-style OR "life style")) OR exercise* OR fitness OR sport* OR "physical exertion" OR "motor activ" OR "train" OR "physical effort" OR "physical endurance" OR "physical condition" OR gymnastic* OR run OR runn* OR swim* OR walk* OR jogg* OR athletic* OR cycl* OR aerobic* OR move OR bicycl*

Species
Humans (screened manually)

Language
No limit